Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Artificial Sweeteners Are Related to Non-Alcoholic Fatty Liver Disease: Microbiota Dysbiosis As a Novel Potential Mechanism Publisher



Emamat H1 ; Ghalandari H2 ; Tangestani H3, 4 ; Abdollahi A5 ; Hekmatdoost A2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Nutrition, Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran
  4. 4. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Nutrition Science, Purdue University, United States

Source: EXCLI Journal Published:2020


Abstract

Non-alcoholic fatty liver disease (NAFLD) is a systemic and wide-spread disease characterized by accumulation of excess fat in the liver of people who drink little or no alcohol. Artificial sweeteners (ASs) or sugar substitutes are food additives that provide a sweet taste, and are also known as low-calorie or non-calorie sweeteners. Recently people consume increasingly more ASs to reduce their calorie intake. Gut microbiome is a complex eco-system where 1014 microorganisms play several roles in host nutrition, bone mineralization, immune system reg-ulation, xenobiotics metabolism, proliferation of intestinal cells, and protection against pathogens. A disruption in composition of the normal microbiota is known as ‘gut dysbiosis’ which may adversely affect body metabo-lism. It has recently been suggested that dysbiosis may contribute to the occurrence of NAFLD. The aim of the present study was to investigate the effects of ASs on the risk of NAFLD. The focus of this review is on micro-biota changes and dysbiosis. Increasing evidence shows that ASs have a potential role in microbiota alteration and dysbiosis. We speculate that increased consumption of ASs can further raise the prevalence of NAFLD. However, further human studies are needed to determine this relationship definitively. © 2020, Leibniz Research Centre for Working Environment and Human Factors. All rights reserved.
Related Docs
View other Related Docs
1. Non-Alcoholic Fatty Liver Diseases: From Role of Gut Microbiota to Microbial-Based Therapies, European Journal of Clinical Microbiology and Infectious Diseases (2020)
2. The Critical Role of Faecalibacterium Prausnitzii in Human Health: An Overview, Microbial Pathogenesis (2020)
3. The Role of Gut Microbiota in Non-Alcoholic Fatty Liver Disease Pathogenesis, Obesity Medicine (2024)
4. Advancing the Global Public Health Agenda for Nafld: A Consensus Statement, Nature Reviews Gastroenterology and Hepatology (2022)
5. Role of Gut Microbiome in Polycystic Ovary Syndrome, Journal of Mazandaran University of Medical Sciences (2021)
6. Fecal Microbiota in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Systematic Review, Archives of Iranian Medicine (2020)
7. Gut Microbiota As a Target in the Pathogenesis of Metabolic Disorders: A New Approach to Novel Therapeutic Agents, Hormone and Metabolic Research (2016)
8. Gut Microbiota Profile in Patients With Nonalcoholic Fatty Liver Disease and Presumed Nonalcoholic Steatohepatitis, Journal of Research in Medical Sciences (2022)
Experts (# of related papers)
View all Related Experts
Mohammad Mehdi Feizabadi (3)
Hossein Poustchi (3)
Other Related Docs
9. Amelioration of Obesity-Induced White Adipose Tissue Inflammation by Bacillus Coagulans T4 in a High-Fat Diet-Induced Obese Murine Model, Life Sciences (2023)
10. Atherogenic Index of Plasma Is an Independent Predictor of Metabolic-Associated Fatty Liver Disease in Patients With Type 2 Diabetes, European Journal of Medical Research (2022)
11. Gut Microbiota in Nonalcoholic Fatty Liver Diseases With and Without Type-2 Diabetes Mellitus, European Journal of Gastroenterology and Hepatology (2021)
12. Association of Allium Vegetables Intake and Non-Alcoholic Fatty Liver Disease Risk: A Case-Control Study, Nutrition and Food Science (2020)
13. The Association of the Healthy Food Diversity Index With the Risk of Non-Alcoholic Fatty Liver Disease Among the Adult Population, Clinical Nutrition ESPEN (2024)
14. Toll-Like Receptors and Metabolic (Dysfunction)-Associated Fatty Liver Disease, Pharmacological Research (2022)
15. Effects of Naringenin Supplementation in Overweight/Obese Patients With Non-Alcoholic Fatty Liver Disease: Study Protocol for a Randomized Double-Blind Clinical Trial, Trials (2021)
16. Dual Role of Microbiota-Derived Short-Chain Fatty Acids on Host and Pathogen, Biomedicine and Pharmacotherapy (2022)
17. Microbes: Possible Link Between Modern Lifestyle Transition and the Rise of Metabolic Syndrome, Obesity Reviews (2019)
18. Effect of Oral and Parenteral Routes of Vitamin D Supplementation on Serum 25(Oh) Vitamin D Levels in Patients With Non-Alcoholic Fatty Liver Disease, Caspian Journal of Internal Medicine (2022)
19. Emerging Role of Nanotechnology in Treatment of Non-Alcoholic Fatty Liver Disease (Nafld), EXCLI Journal (2023)
20. The Therapeutic Effects of Berberine Plus Sitagliptin in a Rat Model of Fatty Liver Disease, Iranian Journal of Basic Medical Sciences (2021)
21. Role of Gut-Liver Axis in Non-Alcoholic Fatty Liver Disease, Iranian Biomedical Journal (2025)